The Japan autoimmune disease diagnostics market size was estimated at USD 383.73 Million in 2025 and is expected to reach USD 640.45 million by 2033, growing at a CAGR of 6.6% from 2025 to 2033. As the world’s fastest-aging nation, with over 29% of its population aged 65 or older, Japan faces a rising prevalence of conditions such as rheumatoid arthritis and autoimmune pancreatitis. This fuels demand for ANA tests, autoantibody panels, and advanced molecular assays. Growth is further supported by innovations in multiplex immunoassays, AI, and biomarker discovery, alongside strong academic-industry collaborations. Partnerships, such as those involving Sysmex, MBL, and Autobio Diagnostics, enhance precision, scalability, and early disease detection.
According to the Statistics Bureau of Japan (October 2023), the country’s population stood at 124.35 million, down by 595,000 people (-0.48%) from the previous year-marking the thirteenth consecutive annual decline. Male and female populations fell to 60.49 million (-0.44%) and 63.86 million (-0.51%), respectively. Natural population decline has persisted for 19 years among men and 15 years among women, reflecting ongoing demographic contraction. However, net migration trends offered some offset, with positive net migration among Japanese citizens for the first time in three years, alongside steady growth in the foreign resident population.
This demographic backdrop directly influences the autoimmune disease diagnostics market. Rheumatoid arthritis (RA), for instance, affects an estimated 822,000 people in Japan (Oxford University Press, May 2024), with peak prevalence among individuals aged 65-85. Given its higher occurrence in older adults, RA illustrates how aging demographics are driving demand for diagnostic services-particularly ANA tests, autoantibody panels, and confirmatory molecular assays.
This product will be delivered within 2 business days.
According to the Statistics Bureau of Japan (October 2023), the country’s population stood at 124.35 million, down by 595,000 people (-0.48%) from the previous year-marking the thirteenth consecutive annual decline. Male and female populations fell to 60.49 million (-0.44%) and 63.86 million (-0.51%), respectively. Natural population decline has persisted for 19 years among men and 15 years among women, reflecting ongoing demographic contraction. However, net migration trends offered some offset, with positive net migration among Japanese citizens for the first time in three years, alongside steady growth in the foreign resident population.
This demographic backdrop directly influences the autoimmune disease diagnostics market. Rheumatoid arthritis (RA), for instance, affects an estimated 822,000 people in Japan (Oxford University Press, May 2024), with peak prevalence among individuals aged 65-85. Given its higher occurrence in older adults, RA illustrates how aging demographics are driving demand for diagnostic services-particularly ANA tests, autoantibody panels, and confirmatory molecular assays.
Japan Autoimmune Disease Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, the analyst has segmented the Japan autoimmune disease diagnostics market based on type, product, test type, and end use:Type Outlook (Revenue, USD Million, 2021-2033)
- Systemic autoimmune disease diagnostics
- Localized autoimmune disease diagnostics
Product Outlook (Revenue, USD Million, 2021-2033)
- Instruments
- Consumables & Assays
Test Type Outlook (Revenue, USD Million, 2021-2033)
- Antinuclear antibody tests
- Autoantibody tests
- C-reactive Protein (CRP)
- Complete blood count (CBC)
- Urinalysis
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Diagnostic Centers
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Japan Autoimmune Disease Diagnostics Market: Methodology and Scope
Chapter 2. Japan Autoimmune Disease Diagnostics Market: Executive Summary
Chapter 3. Japan Autoimmune Disease Diagnostics Market Variables, Trends, & Scope
Chapter 4. Japan Autoimmune Disease Diagnostics Market: Type Estimates & Trend Analysis
Chapter 5. Japan Autoimmune Disease Diagnostics Market: Product Estimates & Trend Analysis
Chapter 6. Japan Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis
Chapter 7. Japan Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Japan Autoimmune Disease Diagnostics market report include:- Fujirebio
- Medical & Biological Laboratories (MBL)
- Bio-Rad Laboratories, Inc.
- Abbott
- F. Hoffmann-La Roche, Ltd.
- Siemens Healthineers AG
- Sysmex Corporation
- BioMérieux
- Beckman Coulter ( Danaher)
- SEKISUI MEDICAL CO., LTD
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 383.73 Million |
| Forecasted Market Value ( USD | $ 640.45 Million |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Japan |
| No. of Companies Mentioned | 11 |
